OXFORD, UNITED KINGDOM - 30 OCTOBER 2025. Beckley Psytech Limited (“Beckley Psytech”), a clinical-stage biopharmaceutical company pioneering the next generation of mental health treatments, today announced that it will be presenting data on the effects of BPL-003, a novel synthetic intranasal formulation of mebufotenin (5-MeO-DMT) benzoate, in patients with treatment-resistant depression (TRD) who were also taking concomitant SSRIs in a poster presentation at the CNS Summit in Boston, United States from November 2 - 5.
Dr Claire Roberts, VP, Head of Clinical Development and Regulatory Affairs at Beckley Psytech, will present a poster titled ‘Intranasal 5-MeO-DMT concomitant with SSRI for treatment-resistant depression: a proof-of-concept trial’ at the poster sessions on Monday 3rd November and Tuesday 4th November between 5pm - 7pm EST. The poster will show that a single dose of BPL-003, administered adjunctively to SSRIs, demonstrated good tolerability and promising clinical evidence of improvement in depressive symptoms, with a rapid onset of action, and meaningful and sustained response for up to three months after dosing.
The findings come from a Phase 2a open-label study of BPL-003 in patients with moderate-to-severe TRD who were taking defined selective serotonin reuptake inhibitors (SSRIs). Topline efficacy results from the study were shared in May 2025.
Speaking on Beckley Psytech’s attendance at the CNS Summit, Dr Claire Roberts says: “The CNS Summit is an important forum for advancing dialogue about neuroscience, mental health and patient care. Sharing our Phase 2a findings here is an opportunity to contribute to the broader understanding of treatment-resistant depression, as well as the role novel investigational compounds like BPL-003 could play as an adjunctive therapy to patients already on SSRIs. While early, these results may help inform future approaches and, over time, offer new possibilities for patients.”
For more information please contact: Charlotte Chorley, Communications Lead, at info@beckleypsytech.com
About Beckley Psytech
Beckley Psytech Ltd is a private biopharmaceutical company dedicated to improving the lives of people living with neuropsychiatric disorders by developing rapid-acting psychedelic medicines. Founded in 2019, and underpinned by more than two decades of pioneering scientific research from the Beckley Foundation, Beckley Psytech combines world-leading psychedelic science with extensive drug development expertise in order to optimise patient outcomes, improve treatment opportunities and ease the burden these conditions have on individuals, healthcare systems and society. For more information about Beckley Psytech, visit www.beckleypsytech.com or follow the Company on LinkedIn.
Links to other websites do not imply affiliation or endorsement. Beckley Psytech does not control and is not responsible for their content.
%20(1).jpg)